Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) were trading midday at $7.96, up $4.62, or 138%, after the company provided an update on etripamil, a short-acting calcium channel blocker ...
The Agency has specifically requested clarification about the time of data recorded for adverse events in the phase 3 trials. The Food and Drug Administration (FDA) has issued a Refusal to File (RTF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback